A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

被引：0
|
作者：
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC),Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1889 / 1896
页数：7
相关论文
共 50 条
  • [31] Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers
    Rousset, Perrine
    Nardin, Charlee
    Maubec, Eve
    Heidelberger, Valentine
    Picard, Alexandra
    Gerard, Emilie
    Kramkimel, Nora
    Steff, Maud
    Quereux, Gaelle
    Gaudy-Marqueste, Caroline
    Lesage, Candice
    Mignard, Claire
    Jeudy, Geraldine
    Jouary, Thomas
    Saint-Jean, Melanie
    Baroudjian, Barouyr
    Archier, Elodie
    Mortier, Laurent
    Lebbe, Celeste
    Montaudie, Henri
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting.
    Sun, Danyang
    Ma, Junxun
    Wang, Jinliang
    Han, Chun
    Qian, Yuanyu
    Chen, Guangying
    Li, Xiaoyan
    Zhang, Juan
    Cui, Pengfei
    Du, Wushuang
    Wu, Zhaozhen
    Chen, Shixue
    Zheng, Xuan
    Yue, Zhichao
    Song, Jia
    Cai, Shangli
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
    Li, Jian-Xu
    Deng, Wen-Xiang
    Huang, Shi-Ting
    Lin, Xiao-Feng
    Long, Mei-Ying
    Zhang, Jie
    Su, Ting-Shi
    Li, Li-Qing
    Pang, Ya-Dan
    Liang, Chun-Feng
    Zhou, Hong-Mei
    Lu, Hai-Yan
    Liang, Shi-Xiong
    Xiang, Bang-De
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [34] Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
    Jian-Xu Li
    Wen-Xiang Deng
    Shi-Ting Huang
    Xiao-Feng Lin
    Mei-Ying Long
    Jie Zhang
    Ting-Shi Su
    Li-Qing Li
    Ya-Dan Pang
    Chun-Feng Liang
    Hong-Mei Zhou
    Hai-Yan Lu
    Shi-Xiong Liang
    Bang-De Xiang
    Radiation Oncology, 17
  • [35] Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
    Rai, R.
    McQuade, J. L.
    Wang, D. Y.
    Park, J. J.
    Nahar, K.
    Sosman, J. A.
    Beckermann, K. E.
    Haydu, L. E.
    Lo, S.
    Rubinstein, S.
    Beckermann, K. E.
    McKean, M.
    Matthew, S.
    Guminski, A.
    Carlino, M. S.
    Davies, M.
    Johnson, D. B.
    Long, G. V.
    Menzies, A. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in China: A retrospective, real-world study.
    Yang, Xin-Rong
    Guo, De-Zhen
    Chen, Fei-Yu
    Fan, Jia
    Jian, Zhou
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers
    An, Tianqi
    Hui, Qiu
    Zong, Hong
    Liu, Linhua
    Cao, Xinguang
    Li, Rui
    Hu, Shuang
    Liu, Yiyi
    Li, Jia
    Zhao, Ruihua
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1647 - 1663
  • [38] Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
    Lv, X.
    Wang, L.
    Su, S.
    Li, R.
    Liu, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1009 - S1009
  • [39] Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population
    Wu, Tiantian
    Pu, Changsheng
    Wang, Qiang
    Zhang, Keming
    BIOMEDICINES, 2023, 11 (11)
  • [40] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Yang, Xu
    Chen, Bowen
    Wang, Yanyu
    Wang, Yunchao
    Long, Junyu
    Zhang, Nan
    Xue, Jingnan
    Xun, Ziyu
    Zhang, Linzhi
    Cheng, Jiamin
    Lei, Jin
    Sun, Huishan
    Li, Yiran
    Lin, Jianzhen
    Xie, Fucun
    Wang, Dongxu
    Pan, Jie
    Hu, Ke
    Guan, Mei
    Huo, Li
    Shi, Jie
    Yu, Lingxiang
    Zhou, Lin
    Zhou, Jinxue
    Lu, Zhenhui
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Lu, Yinying
    Zhao, Haitao
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 709 - 719
12345